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Introduction
Organophosphorus nerve agents are considered to be the 
most dangerous chemical warfare agents. These compounds 
pose potential neurotoxic threats to both military and civil-
ian populations as evidenced by terrorist attacks in Japan 
(Ohtomi et al. 1996). Their acute toxic effects are based on 
the  phosphonylation  of  acetylcholinesterase  (AChE,  EC 
3.1.1.7), leading to the irreversible inhibition of its active site 
and subsequent overstimulation of postsynaptic cholinergic 
receptors  due  to  the  accumulation  of  the  neurotransmit-
ter acetylcholine in synapses of the central and peripheral 
  nervous systems (Marrs 1993; Lotti 2000).
The medical countermeasures of nerve agent poisonings 
include  the  administration  of  the  antidotes  that  are  able 
to counteract the main toxic effects of nerve agents. The 
  standard antidotal treatment of nerve agent poisoning usu-
ally includes an anticholinergic agent to block the overstim-
ulation of cholinergic receptors and an oxime to reactivate 
nerve  agent-inhibited  AChE  (Dawson  1994;  Taylor  1996). 
The compounds with nucleophilic oximate anion were dis-
covered and considered to be able to reactivate nerve agent-
inhibited AChE by dephosphonylating the enzyme active site 
and restoring its activity. However, some nerve agents were 
found to be resistant to standard antidotal treatment. One 
of the most resistant nerve agents is tabun (O-ethyl-N,N-
dimethyl phosphoramidocyanidate). Deleterious effects of 
tabun are extraordinarily difficult to antagonize because of 
the changes in hydrogen bonding and the conformational 
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abstract
The  potency  of  newly  developed  bispyridinium  compounds  (K117,  K127)  to  reduce  tabun-induced  acute 
  neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional 
observational battery. The neuroprotective effects of atropine alone and atropine combined with one of three 
bispyridinium oximes (K117, K127, obidoxime) on rats poisoned with tabun at a sublethal dose (180 μg/kg i.m.; 
80% of LD50 value) were studied. Tabun-induced neurotoxicity was monitored using a functional observational 
battery and automatic measurement of motor activity at 24 h following tabun challenge. The results indicated 
that all tested oximes combined with atropine enabled tabun-poisoned rats to survive 24 h following tabun 
challenge while one tabun-poisoned rats died within 24 h after tabun poisoning when the rats were treated 
with atropine alone. Newly developed oxime K127 combined with atropine was the most effective in decreas-
ing tabun-induced neurotoxicity in the case of sublethal poisonings among all oximes tested. Nevertheless, the 
differences of neuroprotective efficacy between K127 and obidoxime are not sufficient to replace obidoxime by 
K127 for the treatment of acute tabun poisonings.
Keywords:  Atropine, Functional observational battery, Neurotoxicity, Oximes, Tabun
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changes of AChE-tabun complex prior to an aging process 
in the AChE active site (Cabal and Bajgar 1999; Ekström et al. 
2006).
Tabun can produce centrally-mediated seizure activity, 
that rapidly progresses to status epilepticus and contributes 
to profound brain damage (Marrs 1993; Taylor 1996). The 
exposure of experimental animals to tabun in convulsions-
inducing doses may result in irreversible lesions in the central 
nervous system (CNS) that can be manifested as behavioral 
effects in survivors that have convulsed (Jokanovic 1993). 
Therefore, the ability of antidotes to block the acute neuro-
toxic effects of tabun and prevent development of irrevers-
ible lesions in the CNS is important for successful antidotal 
treatment. Generally, the oximes exert more potent effects 
in the peripheral compared to central system due to their 
poor penetration into the CNS. Nevertheless, there are pub-
lished results demonstrating the penetration of oximes into 
CNS and subsequent reactivation of nerve agent-inhibited 
AChE in the brain (Cassel et al. 1997; Sakurada et al. 2003). 
Although the rate of the reactivation of nerve agent-inhib-
ited AChE in the brain is lower compared to the peripheral 
system, the role of CNS is important for survival from nerve 
agent exposure (Marrs 1993; Kassa 2002).
As  the  ability  of  currently  used  monopyridinium  (e.g. 
pralidoxime)  and  bispyridinium  oximes  (e.g.  obidoxime) 
to  counteract  the  neurotoxic  effects  of  tabun  is  generally 
poor (Kassa et al. 2005), the replacement of commonly used 
  oximes with a more effective oxime has been a long-standing 
goal for the treatment of tabun poisoning (Dohnal et al. 2005). 
For  this  purpose,  new  bispyridinium  oximes  K117  [1,5-
bis(4-hydroxyiminomethylpyridinium)-3-oxapentane dibro 
mide]  and  K127  [1-(4-hydroxyiminomethylpyridinium)-5-
(4- carbamoylpyridinium)–3-oxapentane dibromide] (Fig. 1) 
were synthesized (Kim et al. 2005; Musilek et al. 2006) to 
improve the efficacy of antidotal treatment in eliminating 
tabun-induced neurotoxicity.
The aim of this study was to compare the neuroprotec-
tive potency of newly developed oximes (K117, K127) with 
currently  available  oxime  (obidoxime)  in  combination 
with an anticholinergic drug atropine in tabun-poisoned 
rats. The tabun-induced neurotoxic signs were determined 
using  a  functional  observational  battery,  a  non-invasive 
and    relatively  sensitive  type  of  neurological  examination 
for  a  wide  range  of  neurobiological  functions  including 
measurements of sensory, motor, and autonomic nervous 
functions.
Materials and methods
Animals
Male albino Wistar rats weighing 200–230 g were purchased 
from Konarovice (Czech Republic). They were kept in an air-
conditioned room (22 ± 2°C and 50 ± 10% relative humidity, 
with lights from 7.00 to 19.00 h) and allowed access to stand-
ard food and tap water ad libitum. The rats were divided 
into groups of eight animals. Handling of the experimental 
animals was performed in compliance with relevant laws 
and institutional guidelines and done under the supervision 
of the Ethics Committee of the Faculty of Military Health 
Sciences in Hradec Kralove (Czech Republic).
Enzymes and chemicals
Tabun was obtained from Military Technical Institute in Brno 
(Czech Republic) and was 96% pure as assayed by acidimetric 
titration. All oximes studied of 98.5% purity were synthesized 
at the Department of Toxicology of the Faculty of Military 
Health Sciences in Hradec Kralove (Czech Republic). Their 
purities  were  analyzed  using  HPLC.  All  other  drugs  and 
chemicals of analytical grade were obtained commercially 
and used without further purification. All substances were 
administered intramuscularly (i.m.) at a volume of 1 mL/kg 
body weight (b.w.).
In vivo experiments
Tabun  was  administered  at  a  sublethal  dose  (180  g/
kg  b.w.  80%  LD50).  One  minute  following  tabun  chal-
lenge, the rats were treated with atropine (21 mg/kg b.w.) 
alone or in combination with obidoxime, K117 or K127 
in equitoxic doses corresponding to 5% of their LD50 val-
ues (Kassa et al. 2008). The neurotoxicity of tabun was 
monitored using the functional observational battery at 
24 h following tabun poisoning. The evaluated markers 
of tabun-induced neurotoxicity in experimental animals 
were compared with the parameters obtained from con-
trol rats given saline instead of tabun and antidotes at the 
same volume.
The  functional  observational  battery  consists  of  47 
measurements of sensory, motor and autonomic nervous 
  functions. Some of them are scored (Table 1), the others are 
measured in absolute units (Frantik and Hornychova 1995; 
Hornychova et al. 1995; Moser et al. 1997). The first evaluation 
was obtained when tabun-poisoned rats were in the home 
cage. The observer evaluated each animal’s posture, palpe-
bral closure, and involuntary motor movements. Then, each 
rat was removed from the home cage and briefly hand-held. 
The exploratory activity, piloerection, and other skin abnor-
malities were noted. Salivation and nose secretion were also 
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Figure  1.  Chemical structures of oximes studied.234    Jiri Kassa et al.
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registered and scored. Then, the rats were placed on a flat 
surface which served as an open field. A timer was started 
for 3 min during which the frequency of rearing responses 
was recorded. Rearing is the special kind of movement char-
acterized by raising (both forelimbs are put up). This kind 
of movement is typical for exploratory behavior of rats. At 
the same time, gait characteristics were noted and ranked, 
and arousal, stereotypy, and bizarre behaviors and abnor-
mal posture were evaluated. At the end of the third minute, 
the number of fecal boluses and urine pools on the adsorb-
ent pad was registered. Reflex testing comprising recording 
each rat’s response to the frontal approach of the blunt end 
of a pen, a touch of the pen to the posterior flank, and an 
auditory clic stimulus was also used. The response to a pinch 
on the tail and the ability of pupils to constrict in response to 
light were then assessed. These measures were followed by 
a test for the aerial righting reflex and by the measurements 
of forelimb and hindlimb grip strength, body weight, rectal 
temperature, and finally hindlimb landing foot splay. The 
whole battery of tests required approximately 6–8 min per 
rat. The observer of behavior did not know about the design 
of experiments. Motor activity data were collected shortly 
after finishing of the functional observational battery, using 
an apparatus for testing of a spontaneous motor activity of 
laboratory animals (constructed at the Faculty of Military 
Health Sciences, Hradec Kralove, Czech Republic). The ani-
mals were placed for a short period (10 min) in the measur-
ing cage and their movements (total, horizontal, and vertical 
activity) were recorded.
Data analysis
Data collected with the functional observational battery and 
motor activity assessment include categorial, ordinal, and 
continuous values. Statistical analyses were performed on 
a PC with a special interactive program NTX (Frantik and 
Hornychova 1995). The categorial and ordinal values were 
formulated  as  contingency  tables  and  judged  consecu-
tively by Chi-squared test of homogeneity, Concordance-
Discordance test, and Kruskal-Wallis test, respectively. The 
continual data were assessed by successive statistical tests: 
CI for Delta, Barlett test for Equality of Variance, Williams 
test and Test for Distribution Functions (Roth et al. 1962). 
The differences were considered significant when p < 0.05.
Results
Six  of  eight  tabun-poisoned  rats  survived  till  the  end  of 
experiment (24 h following the intoxication). When tabun-
poisoned  rats  were  treated  with  atropine  alone,  seven  of 
eight tabun poisoned rats survived within 24 h after tabun 
challenge. On the other hand, all tabun-poisoned rats treated 
with atropine in combination with one of the tested oximes 
survived till the end of experiment.
The results of the experiments related to the measure-
ment  of  tabun-induced  neurotoxicity  at  24  h  following 
tabun poisoning are divided into three parts (activity and 
neuromuscular  measures,  sensorimotor  and  excitability 
measures, and autonomic measures—Moser et al. 1997) and 
summarized in Tables 2–4. The observation of neurotoxic 
Table  2.  The values of tabun-induced activity and neuromuscular neurotoxic markers measured at 24 h following tabun challenge by the functional 
observational battery (No 1-2, 4-14 scored values, No 3, 15-21 values in absolute units).
 
 
24 hours
 
Controls  
(n = 8)
 
Tabun-A + K117 (n 
= 8)
 
Tabun-A + K127  
(n = 8)
Tabun-A + 
obidoxime  
(n = 8)
 
Tabun-A  
(n = 7)
 
Tabun  
(n = 6)
No Marker x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s
 1 posture  1.00   3.00*    3.00*    3.00*   3.00*   3.00*  
 2 muscular tonus  0.00   −2.00*    0.00    0.00   −2.00*   −2.00*  
 3 rearing  8.25  4.27 0.63* 1.77  5.00 5.71  1.63* 0.92 0.75* 1.75 2.25* 3.11
 4 hyperkinesis  0.00   2.00*    0.00    5.00*   0.00   0.00  
 5 tremors  0.00   2.00*    0.00    2.00*   0.00   0.00  
 6 clonic movements  0.00   1.00*    0.00    1.00*   0.00   0.00  
 7 tonic movements  0.00   3.00*    0.00    0.00   0.00   0.00  
 8 gait  0.00   7.00*    5.00*    0.00   7.00*   1.00*  
 9 ataxia  0.00   2.00*    0.00    0.00   0.00   2.00*  
10 gait score  0.00   2.00*    0.00    0.00   0.00   0.00  
11 mobility score  1.00   3.00*    1.00    1.00   1.00   1.00  
12 activity  4.00   1.00*    4.00    1.00*   2.00*   1.00*  
13 RRF  1.00   1.00    1.00    1.00   1.00   1.00  
14 RRV  1.00   1.00    1.00    1.00   1.00   1.00  
15 landing foot splay (mm) 94.00 12.47 78.63* 12.64 105.50 20.26 111.13* 15.97 89.31 40.57 59.88 39.66
16 forelimb grip strength (kg)  5.75  0.82 4.26* 1.06  5.39 1.11  5.98 0.90 5.13 2.05 4.95 1.01
17 hindlimb grip strength (kg)  1.14  0.22 0.49*  0.20  1.06 0.16  1.06 0.23 0.81* 0.31 0.67* 0.10
18 grip strength of all limbs (kg) 19.01  1.41 11.96* 2.92 19.55 3.79 20.23 2.40 12.93* 6.33 11.30* 2.71
19 vertical activity 121.00 112.29 16.75* 28.22 30.13* 38.04 10.50* 6.55 25.25* 29.49 30.13* 30.34
20 horizontal activity 12.63 17.82 1.88 4.55  2.63 3.11  0.13 0.35 3.25 7.23 3.50 7.21
21 total motor activity 133.63 127.29 18.63* 32.46 32.75 40.70 10.63* 6.67 28.50* 35.94 33.63 36.33
* p < 0.05 (comparison with the control values).236    Jiri Kassa et al.
signs indicated that many functional disorders in poisoned 
rats lasted at least 24 h not only in tabun-poisoned rats but 
also in tabun-poisoned rats treated with atropine alone or 
in combination with K117 and obidoxime. Tabun produced 
passive behavior of rats during handling and retention, mio-
sis, and a decrease in muscule tone at 24 h following tabun 
administration. The exploratory and rearing activity were 
significantly decreased and gait was severely impaired. In 
addition, no reaction during recording each rat’s response 
to  an  auditory  clic  stimulus  was  observed.  Non-treated 
tabun-poisoned  rats  and  tabun-poisoned  rats  treated 
with atropine alone or atropine combined with K117 were 
not able to constrict their pupils in response to light due 
to tabun-induced miosis. A marked decrease in limb grip 
strength, food receiving, body temperature, and spontane-
ous horizontal as well as vertical motor activity were also 
observed at 24 h following tabun challenge (Tables 2–4). 
On the other hand, K127 in combination with atropine was 
able to prevent some tabun-induced signs of neurotoxicity 
observed at 24 h following tabun challenge with the excep-
tion of passive behavior of rats during handling and reten-
tion, miosis, gait impairment, a decrease in food receiving, 
body temperature, and spontaneous horizontal as well as 
vertical motor activity (Tables 2–4).
Discussion
The potency of atropine alone to decrease tabun-induced 
acute neurotoxic signs is very low and corresponds to previ-
ously published results demonstrating that atropine alone 
is not able to prevent tabun-induced seizures and subse-
quent neurotoxic effects including brain damage following 
Table  4.  The values of tabun-induced autonomic neurotoxic markers measured at 24 h following tabun challenge by the functional observational 
battery (Nos 1–7, 10–11, 15 scored values, Nos 8–9, 12–14 values in absolute units).
 
24 hours
 
Controls (n = 8)
 
Tabun-A + K117 (n = 8)
 
Tabun-A + K127 (n = 8)
Tabun-A + 
obidoxime (n = 8)
 
Tabun-A (n = 7)
 
Tabun (n = 6)
No Marker x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s
 1 lacrimation  0.00    0.00    0.00    0.00    0.00    4.00*  
 2 palpebral closure  1.00    1.00    1.00    1.00    1.00    1.00  
 3 endo/exophtalmus  0.00    0.00    0.00    0.00    0.00    0.00  
 4 fur abnormalities  0.00    0.00    0.00    0.00    0.00    0.00  
 5 skin abnormalities  0.00    0.00    0.00    0.00    0.00    0.00  
 6 salivation  0.00    0.00    0.00    0.00    0.00    0.00  
 7 nose secretion  0.00    3.00*    0.00    0.00    0.00    3.00*  
 8 urination  1.25 1.58  2.25 4.46  0.75 1.49  2.88 3.60  1.00 1.29  1.17 2.40
 9 defecation  0.00    0.00    0.00    0.00    0.00    0.00  
10 pupil size  0.00   −2.00*   −2.00*   −1.00*   −2.00*   −2.00*  
11 pupil response  1.00    0.50*    1.00    1.00    0.50*    0.00*  
12 food receiving (%) 100.00 0.00 20.50* 1.60 22.50* 2.67 34.00* 4.28 26.13* 10.84 37.50* 23.15
13 body weight (g) 243.38 16.80 282.88* 12.63 272.88 18.09 287.25* 14.00 223.86 19.55 227.50 12.29
14 body  
temperature (°C)
37.08 0.09 36.20* 0.56 36.47* 0.56 36.73* 0.35 36.54* 0.58 36.70* 0.45
15 respiration  0.00    0.00    0.00    0.00    0.00    0.00  
* p < 0.05 (comparison with the control values).
Table  3.  The values of tabun-induced sensorimotor and excitability neurotoxic markers measured at 24 h following tabun challenge by the functional 
observational battery (scored values).
 
24 hours
 
Controls (n = 8)
Tabun-A +  
K117 (n = 8)
Tabun-A +  
K127 (n = 8)
Tabun-A + 
obidoxime (n = 8)
 
Tabun-A (n = 7)
 
Tabun (n= 6)
No Marker x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s x/M ± s
 1 catch difficulty  2.00   1.00*   1.00*   1.00*   1.00*   1.00*  
 2 ease of handling 2.00   1.00*   1.00*   1.00*   1.00*   1.00*  
 3 arousal (GSC) 1.00   4.00*   2.00*   1.00   4.00   2.00*  
 4 tension 0.00   0.00   0.00   0.00   0.00   0.00  
 5 vocalization 0.00   0.00   0.00   0.00   0.00   0.00  
 6 stereotypy 0.00   0.00   0.00   0.00   0.00   0.00  
 7 bizarre behavior 0.00   0.00   0.00   0.00   0.00   0.00  
 8 approach response 2.00   2.00   2.00   2.00   2.00   1.00  
 9 touch response 2.00   2.00   2.00   2.00   2.00   1.00*  
10 click response 2.00   3.00*   2.00   3.00*   2.00   3.00*  
11 tail-pinch response 2.00   2.00   2.00   2.00   2.00   2.00  
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an exposure to tabun at sublethal and lethal doses (Kassa 
and  Koupilova  2000;  McDonough  et  al.  2000;  Kassa  and 
Kunesova 2006). Therefore, anticholinergic drugs such as 
atropine need to be combined with an AChE reactivator for 
more effective antidotal treatment of tabun poisonings. To 
combine atropine with an oxime, the efficacy of antidotal 
treatment of tabun poisonings is increased, although the 
central reactivating efficacy of oximes is lower compared to 
peripheral reactivating efficacy (Kassa 2002). Pralidoxime, 
a currently available oxime for the treatment of poisonings 
with highly toxic organophosphates (Dawson 1994), seems 
to be practically ineffective in preventing tabun-induced 
neurotoxicity (Kassa and Krejcova 2003). Another commonly 
used oxime (obidoxime) is able to partly eliminate tabun-
induced acute neurotoxicity following i.m. administration 
of tabun at a lethal dose, nevertheless, its neuroprotective 
efficacy is not satisfactory (Kassa and Krejcova 2003; Kassa 
and  Karasova  2007).  The  oxime  HI-6  was  demonstrated 
to be significantly less efficacious to block tabun-induced 
acute neurotoxicity than obidoxime (Kassa and Krejcova 
2003; Kassa and Karasova 2007). The unsatisfactory efficacy 
of the above mentioned oximes to prevent tabun-induced 
acute neurotoxicity can be explained due to low potency of 
these oximes in reactivating tabun-inhibited AChE in vitro 
and in vivo (Puu et al. 1986; Jokanovic et al. 1996; Worek 
et al. 1998).
Our results demonstrate that the newly developed oxime 
K117  is  completely  ineffective  to  reduce  tabun-induced 
acute neurotoxic signs and symptoms while the neuropro-
tective efficacy of another newly developed oxime K127 is 
markedly higher. The difference between neuroprotective 
efficacy of both newly developed oximes corresponds to the 
difference between their reactivating and therapeutic effi-
cacy (Kassa et al. 2008). The low neuroprotective, reactivat-
ing, and therapeutic efficacy of K117 can be caused by low 
dosage due to its high acute toxicity (Kassa et al. 2008). The 
different toxicity of both newly developed oximes is probably 
caused by the differences in their chemical structure. The 
oxime K127 differs from K117 by the presence of carbamoyl 
group that diminishes its toxicity. On the other hand, the 
oxime K117 has two oxime groups that are responsible for 
its higher toxicity in comparison with K127.
The reason for a relatively high efficacy of K127 to reduce 
tabun-induced acute neurotoxic signs and symptoms is 
probably  a  chemical  structure  of  its  molecule  because 
the potency of oximes to counteract the acute toxicity of 
nerve agents depends upon their chemical structure. The 
main structural features which influence their efficacy are 
the oxime functional group (its position and amount), the 
connecting linker for bisquaternary reactivators and other 
substituent(s) on the second heteroaromatic ring (Cabal 
et al. 2004; Kuca et al. 2006; Musilek et al. 2007). For tabun 
poisonings, at least one oxime in position four on the het-
eroaromatic ring is necessary for substantial reactivating, 
therapeutic, and neuroprotective potency, whilst an oxime 
in position two has a low or no capability to counteract 
acute toxicity of tabun (Kuca et al. 2006). Additionally, the 
optimal linker length suitable for tabun intoxication varies 
from three to four carbon–carbon bonds (Cabal et al. 2004). 
The neuroprotective efficacy of the oxime K127 is slightly 
better compared to obidoxime, although its therapeutic 
and  reactivating  efficacy  does  not  prevail  the  effects  of 
obidoxime (Kassa et al. 2008). Additionally, the difference 
of neuroprotective efficacy between K127 and obidoxime 
is not sufficient to replace currently used oximes by K127 
for the treatment of acute tabun poisonings.
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